US5525464A
(en)
|
1987-04-01 |
1996-06-11 |
Hyseq, Inc. |
Method of sequencing by hybridization of oligonucleotide probes
|
US5202231A
(en)
|
1987-04-01 |
1993-04-13 |
Drmanac Radoje T |
Method of sequencing of genomes by hybridization of oligonucleotide probes
|
US5700637A
(en)
|
1988-05-03 |
1997-12-23 |
Isis Innovation Limited |
Apparatus and method for analyzing polynucleotide sequences and method of generating oligonucleotide arrays
|
US6054270A
(en)
|
1988-05-03 |
2000-04-25 |
Oxford Gene Technology Limited |
Analying polynucleotide sequences
|
US5744101A
(en)
|
1989-06-07 |
1998-04-28 |
Affymax Technologies N.V. |
Photolabile nucleoside protecting groups
|
US5800992A
(en)
|
1989-06-07 |
1998-09-01 |
Fodor; Stephen P.A. |
Method of detecting nucleic acids
|
US5143854A
(en)
|
1989-06-07 |
1992-09-01 |
Affymax Technologies N.V. |
Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
|
US5871928A
(en)
|
1989-06-07 |
1999-02-16 |
Fodor; Stephen P. A. |
Methods for nucleic acid analysis
|
EP1086742B2
(en)
|
1991-11-22 |
2007-03-14 |
Affymetrix, Inc. (a Delaware Corporation) |
Combinatorial strategies for polymer synthesis
|
US5807522A
(en)
|
1994-06-17 |
1998-09-15 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods for fabricating microarrays of biological samples
|
US5795716A
(en)
|
1994-10-21 |
1998-08-18 |
Chee; Mark S. |
Computer-aided visualization and analysis system for sequence evaluation
|
GB9718972D0
(en)
|
1996-09-25 |
1997-11-12 |
Zeneca Ltd |
Chemical compounds
|
EP1140840B1
(en)
|
1999-01-13 |
2006-03-22 |
Bayer Pharmaceuticals Corp. |
-g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
|
ATE556713T1
(de)
|
1999-01-13 |
2012-05-15 |
Bayer Healthcare Llc |
Omega-carboxyarylsubstituierte-diphenyl- harnstoffe als p38-kinasehemmer
|
US20020065296A1
(en)
|
1999-01-13 |
2002-05-30 |
Bayer Corporation |
Heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors
|
US7928239B2
(en)
|
1999-01-13 |
2011-04-19 |
Bayer Healthcare Llc |
Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas
|
RU2319693C9
(ru)
|
1999-01-13 |
2008-08-20 |
Байер Копэрейшн |
Производные мочевины (варианты), фармацевтическая композиция (варианты) и способ лечения заболевания, связанного с ростом раковых клеток (варианты)
|
US7141581B2
(en)
|
1999-07-02 |
2006-11-28 |
Agouron Pharmaceuticals, Inc. |
Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
|
TWI262914B
(en)
|
1999-07-02 |
2006-10-01 |
Agouron Pharma |
Compounds and pharmaceutical compositions for inhibiting protein kinases
|
UA72946C2
(uk)
|
1999-11-05 |
2005-05-16 |
Астразенека Аб |
Похідні хіназоліну як інгібітори васкулярного ендотеліального фактора росту (vegf)
|
DE60029138T2
(de)
|
1999-12-22 |
2007-06-06 |
Sugen, Inc., San Francisco |
Verwendung von Indolinonverbindungen zur Herstellung von Pharmazeutika für die Modulation der Funktion c-kit Proteintyrosinkinase
|
ES2290117T3
(es)
|
2000-02-15 |
2008-02-16 |
Sugen, Inc. |
Inhibidores de proteina quinasa 2-indolina sustituida con pirrol.
|
SI1343782T1
(sl)
|
2000-12-21 |
2009-10-31 |
Smithkline Beecham Corp |
Pirimidinamini kot modulatorji angiogeneze
|
US7235576B1
(en)
|
2001-01-12 |
2007-06-26 |
Bayer Pharmaceuticals Corporation |
Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
|
DK1450799T5
(da)
|
2001-12-03 |
2007-09-17 |
Bayer Pharmaceuticals Corp |
Arulurinstofforbindelser sammen med andre cytostatiske eller cytotoksiske midler til behandling af humane cancere
|
SE0104164L
(sv)
|
2001-12-11 |
2003-06-12 |
Ericsson Telefon Ab L M |
Högspännings-mos-transistor
|
NO317200B1
(no)
|
2002-08-09 |
2004-09-13 |
Best Practice Deployment As |
System for trafikkopplaering i et kjoretoy
|
KR20050046751A
(ko)
*
|
2002-09-27 |
2005-05-18 |
오리디스 비오메드 포르슝스-운트 엔트비크룽스 게엠베하 |
폴리펩티드 및 이들을 암호화하는 핵산 및 간질환 및 상피세포암을 예방, 진단 또는 치료하기 위한 이들의 용도
|
CA2528669A1
(en)
*
|
2003-06-09 |
2005-01-20 |
The Regents Of The University Of Michigan |
Compositions and methods for treating and diagnosing cancer
|
ES2371383T3
(es)
|
2003-09-26 |
2011-12-30 |
Exelixis, Inc. |
N-[3-fluoro-4-({6-(metiloxi)-7-[(3-morfolin-4-ilpropil)oxi]quinolin-4-il}oxi)fenil]-n'-(4-fluorofenil)ciclopropan-1,1-dicarboxamida para el tratamiento del cáncer.
|
GB0411378D0
(en)
|
2004-05-21 |
2004-06-23 |
Astrazeneca Ab |
Pharmaceutical compositions
|
WO2006138275A2
(en)
|
2005-06-13 |
2006-12-28 |
The Regents Of The University Of Michigan |
Compositions and methods for treating and diagnosing cancer
|
BRPI0617488A2
(pt)
*
|
2005-10-21 |
2011-07-26 |
Bayer Healthcare Llc |
mÉtodo para a monitoraÇço do estado de uma doenÇa associada a uma via de vegf-165 ativada por ultra-expressço ou por mutaÇço de proteÍna vegf-165 em um paciente, mÉtodo de seleÇço de terapia para um paciente humano com uma doenÇa e mÉtodo de dignàstico para detectar uma doenÇa associada a uma via de vegf-165 ativada por ultra-expressço ou por mutaÇço de proteÍna vegf-165 em um paciente
|
EP1954272A2
(en)
|
2005-10-31 |
2008-08-13 |
Bayer Pharmaceuticals Corporation |
Treatment of cancer with sorafenib
|
US8329408B2
(en)
|
2005-10-31 |
2012-12-11 |
Bayer Healthcare Llc |
Methods for prognosis and monitoring cancer therapy
|
WO2008008733A2
(en)
|
2006-07-10 |
2008-01-17 |
Elan Pharma International Ltd. |
Nanoparticulate sorafenib formulations
|
KR20090071603A
(ko)
|
2006-09-19 |
2009-07-01 |
노파르티스 아게 |
Raf 억제제에 대한 표적 조절, 효능, 진단 및/또는 예후의 바이오마커
|
KR101721161B1
(ko)
|
2007-07-25 |
2017-03-29 |
에자이 알앤드디 매니지먼트 가부시키가이샤 |
암 치료에서 이용하기 위한 멀티키나아제 억제제
|
US20090062368A1
(en)
|
2007-08-29 |
2009-03-05 |
Protia, Llc |
Deuterium-enriched sunitinib
|
US20090062347A1
(en)
|
2007-08-29 |
2009-03-05 |
Protia, Llc |
Deuterium-enriched axitinib
|
WO2009034308A2
(en)
|
2007-09-10 |
2009-03-19 |
Cipla Limited |
Process for the preparation of a raf kinase inhibitor and intermediates for use in the process
|
KR101561314B1
(ko)
*
|
2007-09-26 |
2015-10-16 |
추가이 세이야쿠 가부시키가이샤 |
항il-6 수용체 항체
|
WO2009054004A2
(en)
|
2007-10-22 |
2009-04-30 |
Natco Pharma Limited |
Process for the preparation of sorafenib
|
US20100256392A1
(en)
|
2007-11-21 |
2010-10-07 |
Teva Pharmaceutical Industries Ltd. |
Polymorphs of sunitinib base and processes for preparation thereof
|
EP2253629A1
(en)
|
2007-11-21 |
2010-11-24 |
Teva Pharmaceutical Industries Ltd. |
Polymorphs of racemic sunitinib malate, compositions containing them and preparation thereof
|
AU2009215377A1
(en)
|
2008-02-21 |
2009-08-27 |
Generics [Uk] Limited |
Novel polymorphs and processes for their preparation
|
WO2009106825A1
(en)
|
2008-02-27 |
2009-09-03 |
Cipla Limited |
Polymorphs of sorafenib and salts thereof
|
EP2098521A1
(en)
|
2008-03-06 |
2009-09-09 |
Ratiopharm GmbH |
Crystal forms of N-[2-(diethylamino) ethyl]-5-[fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrolle-3-carboxamide and methods for their prepparation
|
EP2142507A1
(en)
|
2008-03-06 |
2010-01-13 |
Sicor, Inc. |
Process for the preparation of sorafenib and salts thereof
|
KR20100119582A
(ko)
|
2008-03-31 |
2010-11-09 |
테바 파마슈티컬 인더스트리즈 리미티드 |
수니티닙 및 이의 염을 제조하는 방법
|
EP2313396A1
(en)
|
2008-06-23 |
2011-04-27 |
Natco Pharma Limited |
Process for the preparation of high purity sunitinib and its pharmaceutically acceptable salt
|
US8618309B2
(en)
|
2008-07-24 |
2013-12-31 |
Teva Pharmaceutical Industries Ltd. |
Sunitinib and salts thereof and their polymorphs
|
US20110301113A1
(en)
|
2008-09-26 |
2011-12-08 |
Concert Pharmaceuticals Inc. |
Pyridineamine derivatives
|
KR20100051769A
(ko)
|
2008-09-30 |
2010-05-18 |
테바 파마슈티컬 인더스트리즈 리미티드 |
수니티닙 베이스 및 l-말산의 비정질 조성물
|
CA2741087A1
(en)
*
|
2008-10-21 |
2010-04-29 |
Bayer Healthcare Llc |
Identification of signature genes associated with hepatocellular carcinoma
|
EP2181991A1
(en)
|
2008-10-28 |
2010-05-05 |
LEK Pharmaceuticals D.D. |
Novel salts of sunitinib
|
EP2186809A1
(en)
|
2008-11-13 |
2010-05-19 |
LEK Pharmaceuticals D.D. |
New crystal form of sunitinib malate
|
US10262103B2
(en)
*
|
2008-11-18 |
2019-04-16 |
Raphael LEHRER |
Individualized cancer treatment
|
US20100297676A1
(en)
*
|
2009-05-20 |
2010-11-25 |
Nodality, Inc. |
Methods for diagnosis, prognosis and methods of treatment
|
WO2011004200A1
(en)
|
2009-07-10 |
2011-01-13 |
Generics [Uk] Limited |
Novel pyrrole derivatives
|
CN102573477A
(zh)
|
2009-07-16 |
2012-07-11 |
葛兰素惠尔康制造业私人有限公司 |
治疗方法
|
US20120232102A1
(en)
|
2009-09-30 |
2012-09-13 |
Chun-Fang Xu |
Methods Of Administration And Treatment
|
CA2775155A1
(en)
|
2009-10-01 |
2011-04-07 |
Csl Limited |
Method of treatment of philadelphia chromosome positive leukemia
|
WO2011047019A1
(en)
*
|
2009-10-13 |
2011-04-21 |
Yale University |
An objective, quantitative method to predict histological subtype in non-small cell lung cancer
|
WO2011050159A1
(en)
|
2009-10-23 |
2011-04-28 |
Glaxo Wellcome Manufacturing Pte Ltd |
Compositions and processes
|
UY33164A
(es)
|
2010-01-06 |
2011-08-31 |
Glaxo Wellcome Mfg Pte Ltd |
Metodo de tratamiento
|
WO2011100325A2
(en)
|
2010-02-09 |
2011-08-18 |
Sicor Inc. |
Polymorphs of sunitinib salts
|
WO2011104555A2
(en)
|
2010-02-25 |
2011-09-01 |
Generics [Uk] Limited |
Novel process
|
WO2011128699A2
(en)
|
2010-04-16 |
2011-10-20 |
Generics [Uk] Limited |
Novel process
|
TW201206908A
(en)
|
2010-05-05 |
2012-02-16 |
Glaxo Wellcome Mfg Pte Ltd |
Pharmaceutical compositions and methods of making same
|
WO2011146458A1
(en)
|
2010-05-18 |
2011-11-24 |
Glaxo Wellcome Manufacturing Pte Ltd |
Method of administration and treatment
|
WO2012058780A1
(en)
|
2010-11-01 |
2012-05-10 |
Scinopharm (Kunshan) Biochemical Technology Co., Ltd. |
Processes for the preparation of 3-(pyrrol-2-yl)methylene)-2-pyrrolones using 2-silyloxy-pyrroles
|
US9150547B2
(en)
|
2010-11-29 |
2015-10-06 |
Hetero Research Foundation |
Process for the preparation of pazopanib using novel intermediate
|
US10220020B2
(en)
|
2010-12-23 |
2019-03-05 |
Nektar Therapeutics |
Polymer-des-ethyl sunitinib conjugates
|
WO2012103060A1
(en)
|
2011-01-27 |
2012-08-02 |
Glaxo Wellcome Manufacturing Pte Ltd |
Method of administration and treatment
|
US20120214830A1
(en)
*
|
2011-02-22 |
2012-08-23 |
OSI Pharmaceuticals, LLC |
Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma
|
CN102283836B
(zh)
|
2011-06-27 |
2013-01-09 |
苏州大学附属第一医院 |
索拉非尼在制备治疗动脉瘤性自发性蛛网膜下腔出血后发生的早期脑损伤的药物中的应用
|
US20140235678A1
(en)
|
2011-06-28 |
2014-08-21 |
Bayer Healthcare Llc |
Topical Ophthalmological Pharmaceutical Composition containing Sorafenib
|
AU2012294458A1
(en)
|
2011-08-08 |
2014-02-27 |
Caris Life Sciences Switzerland Holdings Gmbh |
Biomarker compositions and methods
|
US20140248372A1
(en)
|
2011-09-19 |
2014-09-04 |
Emory University |
Bone morphogenetic protein pathway activation, compositions for ossification, and methods related thereto
|
WO2013046133A1
(en)
|
2011-09-30 |
2013-04-04 |
Pfizer Inc. |
Pharmaceutical compositions of n-methyl-2-[3-((e)-2-pyridin-2-yl-vinyl)-1h-indazol-6-ylsulfanyl]-benzamide
|
US20140322166A1
(en)
*
|
2011-12-12 |
2014-10-30 |
Stc. Unm |
Gene expression signatures for detection of underlying philadelphia chromosome-like (ph-like) events and therapeutic targeting in leukemia
|
WO2013138522A2
(en)
*
|
2012-03-16 |
2013-09-19 |
Genelux Corporation |
Methods for assessing effectiveness and monitoring oncolytic virus treatment
|
WO2015031604A1
(en)
|
2013-08-28 |
2015-03-05 |
Crown Bioscience, Inc. |
Gene expression signatures predictive of subject response to a multi-kinase inhibitor and methods of using the same
|